Bone Health Technologies is making waves with its novel treatment, Osteoboost. At Endo 2023, the company presented a study showing that Osteoboost is an exceptionally promising intervention for postmenopausal loss of bone density and strength.
The double-blinded, sham-controlled study enrolled 126 postmenopausal women with low bone mass. Those who used Osteoboost saw an 82% reduction in bone strength loss and an 85% reduction in loss of bone density.
Laura Yecies, CEO of Bone Health Technologies, emphasized that the results provide a long-awaited non-pharmacological option for the 53 million Americans suffering from osteopenia.
With its wearable design, Osteoboost delivers targeted vibration to the lumbar spine and hips. It represents a breakthrough in the industry, with no serious adverse effects reported.
Bone Health Technologies has achieved a remarkable milestone, and Osteoboost is poised to revolutionize the bone health industry.
